Who is sponsoring NCT00736034?

NCT00736034 is sponsored by Enzymotec.

What condition does NCT00736034 study?

NCT00736034 studies Memory Impairment.

What drugs are being tested in NCT00736034?

Interventions: Phosphatidylserine-Omega3 (SharpPS™-Gold).

What is the status of NCT00736034?

NCT00736034 is currently COMPLETED.

Last reviewed 2010-03-26 · How we verify

A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment

NCT00736034 Phase 4 COMPLETED Results posted

The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment. This study is a single-center, open-label 15 weeks duration trial to assess efficacy of Phosphatidylserine-Omega3 in elderly subjects with memory impairment.

Details

Lead sponsor	Enzymotec
Phase	Phase 4
Status	COMPLETED
Enrolment	18
Start date	2008-09
Completion	2009-04

Conditions

Memory Impairment

Interventions

Phosphatidylserine-Omega3 (SharpPS™-Gold)

Primary outcomes

Change From Baseline in Neuropsychological Computerized Test — baseline, 15 weeks
The computerized neuropsychological assessment software consists of seven separate tasks: symbol spotting, pattern identification, pattern recall, digit-symbol substitution, digits span forward, digits span backward and delayed pattern recall. Based on the results obtained in the single tasks, eight cognitive composite scores are calculated including focused attention, sustained attention, memory recognition \& recall, visuospatial learning, spatial short term memory, executive functions and mental flexibility.The total score range is from 0 to 100 points(0 is worse, 100 is best).

Countries

Israel